Sanli Pharmaceutical: acquires 16 drug market licenses for a transfer price of 2 million yuan.

Sanli Pharmaceutical announced that the company has signed a Drug Marketing Authorization Holder Transfer Agreement with Guizhou Hanfang Pharmaceutical Co., Ltd., agreeing to transfer the marketing authorization and related rights of 16 drugs held by Hanfang Pharmaceutical to the company, with cisplatin sodium chloride injection as the core product of this transfer. The total transfer price is 2 million RMB. This transaction is not considered a related party transaction or a major asset restructuring. According to the rules of the Shanghai Stock Exchange and the company's articles of association, the matters involved in this transaction do not need to be submitted for approval by the board of directors or shareholders' meeting. The change of the drug marketing authorization holder still requires approval from the drug regulatory department, and there is uncertainty regarding the successful completion of the change.